The pet internal deworming industry trends have shown significant momentum in the past 12–18 months, driven by innovation and strategic collaborations. Notably, Zoetis and Elanco expanded their partnership to co-develop pipeline products leveraging AI-driven parasitic disease prediction models, while Virbac acquired a Canadian startup, PuraVet, to bolster its portfolio of natural deworming solutions. Regulatory shifts, such as the FDA’s 2023 approval of a broad-spectrum, low-side-effect dewormer for cats, have spurred product differentiation. Meanwhile, Ceva Santé Animale launched a palatable chewable tablet targeting multi-cat households, addressing consumer demand for ease of administration. The rise of tele-veterinary services has also fueled demand for at-home deworming kits, with companies like VetGuard securing $8M in Series A funding to digitize diagnostics. Furthermore, the EMA revised guidelines in late 2024 to classify certain over-the-counter dewormers as veterinary-prescribed only, tightening market access while emphasizing safety. As pet ownership grows in Asia-Pacific, firms like Bayer and Merck Animal Health are scaling localized formulations to cater to regional parasite profiles, signaling long-term investments in emerging markets.
